UC BON.CAP.CERT. 03/25 PFE/ DE000HD4AP27 /
2024-11-15 9:00:07 AM | Chg.-0.170 | Bid9:47:57 AM | Ask9:47:57 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
29.470EUR | -0.57% | 29.460 Bid Size: 500 |
29.740 Ask Size: 500 |
PFIZER INC. D... | - - | 2025-03-28 | Call |
GlobeNewswire
09-03
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire
08-22
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire
08-16
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
GlobeNewswire
07-17
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire
06-27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
06-05
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire
06-03
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire
05-16
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire
05-09
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03-22
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
03-07
BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...